# Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children

> **NCT07509047** · PHASE2 · RECRUITING · sponsor: **International Vaccine Institute** · enrollment: 390 (estimated)

## Conditions studied

- Cholera Vaccination

## Interventions

- **BIOLOGICAL:** OSP:rTTHc CCV 25 ㎍ with Aluminum phosphate
- **BIOLOGICAL:** OSP:rTTHc CCV 25 ㎍ without Aluminum phosphate
- **BIOLOGICAL:** Euvichol®-Plus
- **OTHER:** Placebo
- **BIOLOGICAL:** CCV with Aluminum, Euvichol®-Plus
- **BIOLOGICAL:** CCV without Aluminum, Euvichol®-Plus

## Key facts

- **NCT ID:** NCT07509047
- **Lead sponsor:** International Vaccine Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-13
- **Primary completion:** 2027-03
- **Final completion:** 2027-12
- **Target enrollment:** 390 (ESTIMATED)
- **Last updated:** 2026-04-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07509047

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07509047, "Age-descending Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Adults and Children". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07509047. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*